INNOGEN-B (02591) core product included in the "National Medical Insurance Drug List"
Yinuo Medicine-B (02591) announced that the group's core product (ie. Ipragliflozin) has been successfully included in the latest version of China's National Reimbursement Drug List (2025 Edition) for the treatment of type 2 diabetes ("T2D") indications. The latest version of the National Reimbursement Drug List will officially take effect on January 1, 2026.
INNOGEN-B (02591) announces that the group's core product (i.e. exenatide alpha) has successfully been included in the latest version of China's National Drug Reimbursement List (2025 edition) for the treatment of type 2 diabetes ("T2D"). The latest version of the National Drug Reimbursement List will officially take effect on January 1, 2026.
Related Articles
Jiangsu Hengrui Pharmaceuticals (01276) has adjusted 20 products/indications to the new national medical insurance list. Among them, 10 products are included for the first time.
CHINA BOTON (03318) will be suspended from trading starting December 8th for a short period, awaiting the announcement of a significant sale transaction.
GMTEight List of A-share restricted sales and lifting restrictions | December 8th
Jiangsu Hengrui Pharmaceuticals (01276) has adjusted 20 products/indications to the new national medical insurance list. Among them, 10 products are included for the first time.
CHINA BOTON (03318) will be suspended from trading starting December 8th for a short period, awaiting the announcement of a significant sale transaction.
GMTEight List of A-share restricted sales and lifting restrictions | December 8th
